Genetic/Familial High-Risk Assessment: Breast and Ovarian

View More View Less
Restricted access
  • 1.

    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759767.

  • 2.

    Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138141.

  • 3.

    Lynch HT, Watson P, Conway TA, Lynch JF. Clinical/genetic features in hereditary breast cancer. Breast Cancer Res Treat 1990;15:6371.

  • 4.

    Pharoah PD, Day NE, Duffy S et al. . Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997;71:800809.

    • Search Google Scholar
    • Export Citation
  • 5.

    Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns 2007;16:241260.

    • Search Google Scholar
    • Export Citation
  • 6.

    Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359:21432153.

  • 7.

    Trepanier A, Ahrens M, McKinnon W et al. . Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns 2004;13:83114.

    • Search Google Scholar
    • Export Citation
  • 8.

    Pharoah PD, Antoniou A, Bobrow M et al. . Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:3336.

  • 9.

    Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 1998;16:19691977.

  • 10.

    Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171182.

  • 11.

    Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009;18:1327.

  • 12.

    Schneider KA, Garber J. (Updated February 9, 2010) Li-Fraumeni syndrome. In GeneReviews at GeneTests: Medical Genetics Information Resource (database online); Copyright, University of Washington, Seattle. 19972010. Available at: http://www.genetests.org. Accessed March 3, 2010.

    • Search Google Scholar
    • Export Citation
  • 13.

    Brooks-Wilson AR, Kaurah P, Suriano G et al. . Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004;41:508517.

    • Search Google Scholar
    • Export Citation
  • 14.

    Kaurah P, MacMillan A, Boyd N et al. . Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007;297:23602372.

    • Search Google Scholar
    • Export Citation
  • 15.

    Schrader KA, Masciari S, Boyd N et al. . Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer 2008;7:7382.

  • 16.

    Masciari S, Larsson N, Senz J et al. . Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 2007;44:726731.

  • 17.

    Oliveira C, Bordin MC, Grehan N et al. . Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 2002;19:510517.

    • Search Google Scholar
    • Export Citation
  • 18.

    Simon R, Zhang X. On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations. Int J Cancer 2008;122:19161917.

    • Search Google Scholar
    • Export Citation
  • 19.

    ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113:957966.

  • 20.

    Whittemore AS. Risk of breast cancer in carriers of BRCA gene mutations. N Engl J Med 1997;337:788789.

  • 21.

    Metcalfe KA, Poll A, Royer R et al. . Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 2010;28:387391.

  • 22.

    Bergman A, Einbeigi Z, Olofsson U et al. . The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 2001;9:787793.

    • Search Google Scholar
    • Export Citation
  • 23.

    Csokay B, Udvarhelyi N, Sulyok Z et al. . High frequency of germline BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 1999;59:995998.

    • Search Google Scholar
    • Export Citation
  • 24.

    Ji J, Hemminki K. Familial risk for histology-specific bone cancers: an updated study in Sweden. Eur J Cancer 2006;42:23432349.

  • 25.

    Mikaelsdottir EK, Valgeirsdottir S, Eyfjord JE, Rafnar T. The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res 2004;6:R284290.

    • Search Google Scholar
    • Export Citation
  • 26.

    Petrij-Bosch A, Peelen T, van Vliet M et al. . BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 1997;17:341345.

    • Search Google Scholar
    • Export Citation
  • 27.

    Tonin PN, Mes-Masson AM, Futreal PA et al. . Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 1998;63:13411351.

    • Search Google Scholar
    • Export Citation
  • 28.

    Ford D, Easton DF, Stratton M et al. . Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676689.

    • Search Google Scholar
    • Export Citation
  • 29.

    Yun MH, Hiom K. Understanding the functions of BRCA1 in the DNA-damage response. Biochem Soc Trans 2009;37:597604.

  • 30.

    Cipak L, Watanabe N, Bessho T. The role of BRCA2 in replication-coupled DNA interstrand cross-link repair in vitro. Nat Struct Mol Biol 2006;13:729733.

    • Search Google Scholar
    • Export Citation
  • 31.

    Wooster R, Neuhausen SL, Mangion J et al. . Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13 Science 1994;265:20882090.

    • Search Google Scholar
    • Export Citation
  • 32.

    Abeliovich D, Kaduri L, Lerer I et al. . The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505514.

    • Search Google Scholar
    • Export Citation
  • 33.

    Levy-Lahad E, Catane R, Eisenberg S et al. . Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997;60:10591067.

    • Search Google Scholar
    • Export Citation
  • 34.

    Petrucelli N, Daly MB, Bars Culver JO, Feldman GL. (Updated June 19, 2007). BRCA1 and BRCA2 hereditary breast/ovarian cancer. In GeneReviews at GeneTests: Medical Genetics Information Resource (database online); Copyright, University of Washington, Seattle. 19972010. Available at: http://www.genetests.org. Accessed March 3, 2010.

    • Search Google Scholar
    • Export Citation
  • 35.

    Antoniou A, Pharoah PD, Narod S et al. . Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:11171130.

    • Search Google Scholar
    • Export Citation
  • 36.

    Ford D, Easton DF, Bishop DT et al. . Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692695.

  • 37.

    King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643646.

  • 38.

    Finch A, Beiner M, Lubinski J et al. . Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006;296:185192.

    • Search Google Scholar
    • Export Citation
  • 39.

    Risch HA, McLaughlin JR, Cole DE et al. . Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700710.

    • Search Google Scholar
    • Export Citation
  • 40.

    Atchley DP, Albarracin CT, Lopez A et al. . Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:42824288.

    • Search Google Scholar
    • Export Citation
  • 41.

    Lakhani SR, Reis-Filho JS, Fulford L et al. . Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:51755180.

    • Search Google Scholar
    • Export Citation
  • 42.

    Lakhani SR, Van De Vijver MJ, Jacquemier J et al. . The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:23102318.

    • Search Google Scholar
    • Export Citation
  • 43.

    Young SR, Pilarski RT, Donenberg T et al. . The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009;9:86.

    • Search Google Scholar
    • Export Citation
  • 44.

    Kirchhoff T, Kauff ND, Mitra N et al. . BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004;10:29182921.

  • 45.

    Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:13101316.

  • 46.

    Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004;22:735742.

    • Search Google Scholar
    • Export Citation
  • 47.

    Narod SA, Neuhausen S, Vichodez G et al. . Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008;99:371374.

  • 48.

    Ferrone CR, Levine DA, Tang LH et al. . BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433438.

  • 49.

    Hahn SA, Greenhalf B, Ellis I et al. . BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003;95:214221.

  • 50.

    Lorenzo Bermejo J, Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol 2004;15:18341841.

    • Search Google Scholar
    • Export Citation
  • 51.

    Beiner ME, Finch A, Rosen B et al. . The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007;104:710.

    • Search Google Scholar
    • Export Citation
  • 52.

    Jazaeri AA, Lu K, Schmandt R et al. . Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003;36:5359.

    • Search Google Scholar
    • Export Citation
  • 53.

    Berchuck A, Heron KA, Carney ME et al. . Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998;4:24332437.

  • 54.

    Bjorge T, Lie AK, Hovig E et al. . BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer 2004;91:18291834.

    • Search Google Scholar
    • Export Citation
  • 55.

    Lakhani SR, Manek S, Penault-Llorca F et al. . Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10:24732481.

  • 56.

    Press JZ, De Luca A, Boyd N et al. . Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.

    • Search Google Scholar
    • Export Citation
  • 57.

    Pal T, Permuth-Wey J, Betts JA et al. . BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:28072816.

    • Search Google Scholar
    • Export Citation
  • 58.

    Risch HA, McLaughlin JR, Cole DE et al. . Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:16941706.

    • Search Google Scholar
    • Export Citation
  • 59.

    Gayther SA, Russell P, Harrington P et al. . The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 1999;65:10211029.

    • Search Google Scholar
    • Export Citation
  • 60.

    Sekine M, Nagata H, Tsuji S et al. . Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. Hum Mol Genet 2001;10:14211429.

    • Search Google Scholar
    • Export Citation
  • 61.

    Lynch HT, Casey MJ, Snyder CL et al. . Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009;3:97137.

    • Search Google Scholar
    • Export Citation
  • 62.

    Kauff ND, Mitra N, Robson ME et al. . Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst 2005;97:13821384.

    • Search Google Scholar
    • Export Citation
  • 63.

    Couch FJ, Farid LM, DeShano ML et al. . BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996;13:123125.

  • 64.

    Friedman LS, Gayther SA, Kurosaki T et al. . Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997;60:313319.

    • Search Google Scholar
    • Export Citation
  • 65.

    Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410419.

  • 66.

    American Chemical Society. What are the key statistics about breast cancer in men? Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_male_breast_cancer_28.asp. Accessed on March 3, 2010.

    • Search Google Scholar
    • Export Citation
  • 67.

    Sidransky D, Tokino T, Helzlsouer K et al. . Inherited p53 gene mutations in breast cancer. Cancer Res 1992;52:29842986.

  • 68.

    Gonzalez KD, Noltner KA, Buzin CH et al. . Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009;27:12501256.

    • Search Google Scholar
    • Export Citation
  • 69.

    Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:1516.

  • 70.

    Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323331.

  • 71.

    Garber JE, Goldstein AM, Kantor AF et al. . Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991;51:60946097.

  • 72.

    Nichols KE, Malkin D, Garber JE et al. . Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001;10:8387.

    • Search Google Scholar
    • Export Citation
  • 73.

    Siddiqui R, Onel K, Facio F et al. . The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Fam Cancer 2005;4:177181.

    • Search Google Scholar
    • Export Citation
  • 74.

    Birch JM, Hartley AL, Tricker KJ et al. . Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:12981304.

    • Search Google Scholar
    • Export Citation
  • 75.

    Krutilkova V, Trkova M, Fleitz J et al. . Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer 2005;41:15971603.

    • Search Google Scholar
    • Export Citation
  • 76.

    Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71:747752.

  • 77.

    Li FP, Fraumeni JF Jr, Mulvihill JJ et al. . A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:53585362.

  • 78.

    Malkin D, Li FP, Strong LC et al. . Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:12331238.

    • Search Google Scholar
    • Export Citation
  • 79.

    Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome—a molecular and clinical review. Br J Cancer 1997;76:114.

  • 80.

    Hisada M, Garber JE, Fung CY et al. . Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606611.

  • 81.

    Lustbader ED, Williams WR, Bondy ML et al. . Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 1992;51:344356.

    • Search Google Scholar
    • Export Citation
  • 82.

    Chompret A, Abel A, Stoppa-Lyonnet D et al. . Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001;38:4347.

    • Search Google Scholar
    • Export Citation
  • 83.

    Birch JM, Blair V, Kelsey AM et al. . Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 1998;17:10611068.

    • Search Google Scholar
    • Export Citation
  • 84.

    Chompret A. The Li-Fraumeni syndrome. Biochimie 2002;84:7582.

  • 85.

    Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 1995;25:101124.

  • 86.

    Bougeard G, Sesboue R, Baert-Desurmont S et al. . Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008;45:535538.

    • Search Google Scholar
    • Export Citation
  • 87.

    Ginsburg OM, Akbari MR, Aziz Z et al. . The prevalence of germline TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 2009;8:563567.

    • Search Google Scholar
    • Export Citation
  • 88.

    Lloyd KM II, Dennis M. Cowden's disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 1963;58:136142.

  • 89.

    Nelen MR, Kremer H, Konings IB et al. . Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999;7:267273.

    • Search Google Scholar
    • Export Citation
  • 90.

    Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2004;41:323326.

    • Search Google Scholar
    • Export Citation
  • 91.

    Eng C. PTEN hamartoma tumor syndrome (PTHS). GeneReviews Web site. Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=phts#phts. Accessed March 3, 2010.

    • Search Google Scholar
    • Export Citation
  • 92.

    Biesecker LG, Rosenberg MJ, Vacha S et al. . PTEN mutations and proteus syndrome. Lancet 2001;358:20792080.

  • 93.

    Orloff MS, Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 2008;27:53875397.

  • 94.

    Starink TM, van der Veen JP, Arwert F et al. . The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 1986;29:222233.

  • 95.

    Brownstein MH, Wolf M, Bikowski JB. Cowden's disease: a cutaneous marker of breast cancer. Cancer 1978;41:23932398.

  • 96.

    Harach HR, Soubeyran I, Brown A et al. . Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol 1999;3:331340.

  • 97.

    Zbuk KM, Eng C. Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol 2007;4:492502.

  • 98.

    Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med 2009;11:687694.

  • 99.

    Black D, Bogomolniy F, Robson ME et al. . Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecol Oncol 2005;96:2124.

  • 100.

    Nelen MR, Padberg GW, Peeters EA et al. . Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996;13:114116.

  • 101.

    Schaffer JV, Kamino H, Witkiewicz A et al. . Mucocutaneous neuromas: an underrecognized manifestation of PTEN hamartoma-tumor syndrome. Arch Dermatol 2006;142:625632.

    • Search Google Scholar
    • Export Citation
  • 102.

    Brownstein MH, Mehregan AH, Bikowski JB et al. . The dermatopathology of Cowden's syndrome. Br J Dermatol 1979;100:667673.

  • 103.

    Brownstein MH, Mehregan AH, Bilowski JB. Trichilemmomas in Cowden's disease. JAMA 1977;238:26.

  • 104.

    Al-Thihli K, Palma L, Marcus V et al. . A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis. Nat Clin Pract Gastroenterol Hepatol 2009;6:184189.

    • Search Google Scholar
    • Export Citation
  • 105.

    Zhou XP, Waite KA, Pilarski R et al. . Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 2003;73:404411.

    • Search Google Scholar
    • Export Citation
  • 106.

    Andres RH, Guzman R, Weis J et al. . Lhermitte-Duclos disease with atypical vascularization—case report and review of the literature. Clin Neuropathol 2009;28:8390.

    • Search Google Scholar
    • Export Citation
  • 107.

    Butler MG, Dasouki MJ, Zhou XP et al. . Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 2005;42:318321.

    • Search Google Scholar
    • Export Citation
  • 108.

    Herman GE, Butter E, Enrile B et al. . Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. Am J Med Genet 2007;143:589593.

    • Search Google Scholar
    • Export Citation
  • 109.

    Herman GE, Henninger N, Ratliff-Schaub K et al. . Genetic testing in autism: how much is enough? Genet Med 2007;9:268274.

  • 110.

    Orrico A, Galli L, Buoni S et al. . Novel PTEN mutations in neurodevelopmental disorders and macrocephaly. Clin Genet 2009;75:195198.

  • 111.

    Varga EA, Pastore M, Prior T et al. . The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med 2009;11:111117.

    • Search Google Scholar
    • Export Citation
  • 112.

    Roche AF, Mukherjee D, Guo SM, Moore WM. Head circumference reference data: birth to 18 years. Pediatrics 1987;79:706712.

  • 113.

    Gorlin RJ, Cohen MM Jr, Condon LM, Burke BA. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1992;44:307314.

  • 114.

    Marsh DJ, Coulon V, Lunetta KL et al. . Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7:507515.

    • Search Google Scholar
    • Export Citation
  • 115.

    Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000;37:828830.

  • 116.

    Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003;22:183198.

  • 117.

    Murff HJ, Byrne D, Syngal S. Cancer risk assessment: quality and impact of the family history interview. Am J Prev Med 2004;27:239245.

  • 118.

    Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 2004;292:14801489.

    • Search Google Scholar
    • Export Citation
  • 119.

    Colditz GA, Willett WC, Hunter DJ et al. . Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA 1993;270:338343.

    • Search Google Scholar
    • Export Citation
  • 120.

    Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 1993;270:15631568.

    • Search Google Scholar
    • Export Citation
  • 121.

    Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643651.

    • Search Google Scholar
    • Export Citation
  • 122.

    Antoniou AC, Hardy R, Walker L et al. . Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008;45:425431.

    • Search Google Scholar
    • Export Citation
  • 123.

    Parmigiani G, Chen S, Iversen ES Jr et al. . Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 2007;147:441450.

  • 124.

    Saslow D, Boetes C, Burke W et al. . American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:7589.

    • Search Google Scholar
    • Export Citation
  • 125.

    Bluman LG, Rimer BK, Berry DA et al. . Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol 1999;17:10401046.

    • Search Google Scholar
    • Export Citation
  • 126.

    Bennett RL, French KS, Resta RG, Doyle DL. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns 2008;17:424433.

    • Search Google Scholar
    • Export Citation
  • 127.

    Bennett RL, Steinhaus KA, Uhrich SB et al. . Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. Am J Hum Genet 1995;56:745752.

    • Search Google Scholar
    • Export Citation
  • 128.

    Calzone KA, Soballe PW. Genetic testing for cancer susceptibility. Surg Clin North Am 2008;88:705721, v.

  • 129.

    Weitzel JN, Lagos VI, Cullinane CA et al. . Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007;297:25872595.

    • Search Google Scholar
    • Export Citation
  • 130.

    Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer 1996;78:10241034.

  • 131.

    Osborne MP, Hoda SA. Current management of lobular carcinoma in situ of the breast. Oncology (Williston Park) 1994;8:4549; discussion 49, 53–44.

    • Search Google Scholar
    • Export Citation
  • 132.

    Beral V, Doll R, Hermon C et al. . Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303314.

    • Search Google Scholar
    • Export Citation
  • 133.

    Chlebowski RT, Hendrix SL, Langer RD et al. . Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:32433253.

    • Search Google Scholar
    • Export Citation
  • 134.

    Rossouw JE, Anderson GL, Prentice RL et al. . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321333.

    • Search Google Scholar
    • Export Citation
  • 135.

    Weiss LK, Burkman RT, Cushing-Haugen KL et al. . Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol 2002;100:11481158.

  • 136.

    Genetic Information Nondiscrimination Act of 2008 (GINA). Vol. Public Law No. 110–233.

  • 137.

    American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:23972406.

    • Search Google Scholar
    • Export Citation
  • 138.

    Robson ME, Storm CD, Weitzel J et al. . American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010;28:893901.

    • Search Google Scholar
    • Export Citation
  • 139.

    Bougeard G, Baert-Desurmont S, Tournier I et al. . Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006;43:531533.

    • Search Google Scholar
    • Export Citation
  • 140.

    Chibon F, Primois C, Bressieux JM et al. . Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approach. J Med Genet 2008;45:657665.

    • Search Google Scholar
    • Export Citation
  • 141.

    Palma MD, Domchek SM, Stopfer J et al. . The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res 2008;68:70067014.

    • Search Google Scholar
    • Export Citation
  • 142.

    Weitzel JN, Lagos VI, Herzog JS et al. . Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 2007;16:16151620.

    • Search Google Scholar
    • Export Citation
  • 143.

    Mohamad HB, Apffelstaedt JP. Counseling for male BRCA mutation carriers: a review. Breast 2008;17:441450.

  • 144.

    Offit K, Levran O, Mullaney B et al. . Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003;95:15481551.

    • Search Google Scholar
    • Export Citation
  • 145.

    Offit K, Sagi M, Hurley K. Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine. JAMA 2006;296:27272730.

    • Search Google Scholar
    • Export Citation
  • 146.

    Warner E, Plewes DB, Hill KA et al. . Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:13171325.

    • Search Google Scholar
    • Export Citation
  • 147.

    Kriege M, Brekelmans CT, Boetes C et al. . Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427437.

    • Search Google Scholar
    • Export Citation
  • 148.

    Leach MO, Boggis CR, Dixon AK et al. . Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:17691778.

    • Search Google Scholar
    • Export Citation
  • 149.

    Stoutjesdijk MJ, Boetes C, Jager GJ et al. . Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001;93:10951102.

    • Search Google Scholar
    • Export Citation
  • 150.

    Kuhl CK, Schrading S, Leutner CC et al. . Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23:84698476.

    • Search Google Scholar
    • Export Citation
  • 151.

    Tilanus-Linthorst M, Verhoog L, Obdeijn IM et al. . A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002;102:9195.

    • Search Google Scholar
    • Export Citation
  • 152.

    Evans DG, Gaarenstroom KN, Stirling D et al. . Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2009;46:593597.

    • Search Google Scholar
    • Export Citation
  • 153.

    Woodward ER, Sleightholme HV, Considine AM et al. . Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 2007;114:15001509.

    • Search Google Scholar
    • Export Citation
  • 154.

    Hartmann LC, Schaid DJ, Woods JE et al. . Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:7784.

    • Search Google Scholar
    • Export Citation
  • 155.

    Hartmann LC, Sellers TA, Schaid DJ et al. . Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:16331637.

    • Search Google Scholar
    • Export Citation
  • 156.

    Meijers-Heijboer H, van Geel B, van Putten WL et al. . Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159164.

    • Search Google Scholar
    • Export Citation
  • 157.

    Rebbeck TR, Friebel T, Lynch HT et al. . Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:10551062.

    • Search Google Scholar
    • Export Citation
  • 158.

    van Dijk S, van Roosmalen MS, Otten W, Stalmeier PF. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. J Clin Oncol 2008;26:23582363.

    • Search Google Scholar
    • Export Citation
  • 159.

    Morrow M, Mehrara B. Prophylactic mastectomy and the timing of breast reconstruction. Br J Surg 2009;96:12.

  • 160.

    Levine DA, Argenta PA, Yee CJ et al. . Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21:42224227.

    • Search Google Scholar
    • Export Citation
  • 161.

    Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993;71:27512755.

    • Search Google Scholar
    • Export Citation
  • 162.

    Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000;83:13011308.

    • Search Google Scholar
    • Export Citation
  • 163.

    Satagopan JM, Boyd J, Kauff ND et al. . Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002;8:37763781.

    • Search Google Scholar
    • Export Citation
  • 164.

    Rebbeck TR, Lynch HT, Neuhausen SL et al. . Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:16161622.

  • 165.

    Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:8087.

    • Search Google Scholar
    • Export Citation
  • 166.

    Finch A, Shaw P, Rosen B et al. . Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006;100:5864.

    • Search Google Scholar
    • Export Citation
  • 167.

    Kauff ND, Satagopan JM, Robson ME et al. . Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:16091615.

    • Search Google Scholar
    • Export Citation
  • 168.

    Kemel Y, Kauff ND, Robson ME et al. . Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 1013.

    • Search Google Scholar
    • Export Citation
  • 169.

    Rebbeck TR, Levin AM, Eisen A et al. . Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:14751479.

    • Search Google Scholar
    • Export Citation
  • 170.

    Eisen A, Lubinski J, Klijn J et al. . Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:74917496.

    • Search Google Scholar
    • Export Citation
  • 171.

    Kauff ND, Domchek SM, Friebel TM et al. . Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:13311337.

    • Search Google Scholar
    • Export Citation
  • 172.

    Powell CB, Kenley E, Chen LM et al. . Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005;23:127132.

    • Search Google Scholar
    • Export Citation
  • 173.

    Rebbeck TR, Friebel T, Wagner T et al. . Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23:78047810.

    • Search Google Scholar
    • Export Citation
  • 174.

    Eisen A, Lubinski J, Gronwald J et al. . Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:13611367.

    • Search Google Scholar
    • Export Citation
  • 175.

    Chlebowski RT, Prentice RL. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. J Natl Cancer Inst 2008;100:13411343.

    • Search Google Scholar
    • Export Citation
  • 176.

    Garber JE, Hartman AR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price? J Clin Oncol 2004;22:978980.

  • 177.

    King MC, Wieand S, Hale K et al. . Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:22512256.

    • Search Google Scholar
    • Export Citation
  • 178.

    McLaughlin JR, Risch HA, Lubinski J et al. . Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007;8:2634.

    • Search Google Scholar
    • Export Citation
  • 179.

    Narod SA, Risch H, Moslehi R et al. . Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424428.

    • Search Google Scholar
    • Export Citation
  • 180.

    Haile RW, Thomas DC, McGuire V et al. . BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 2006;15:18631870.

    • Search Google Scholar
    • Export Citation
  • 181.

    Narod SA, Dube MP, Klijn J et al. . Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:17731779.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2315 764 18
PDF Downloads 389 146 24
EPUB Downloads 0 0 0